Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):86–91. doi: 10.1128/aac.40.1.86

Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

D George 1, P Miniter 1, V T Andriole 1
PMCID: PMC163062  PMID: 8787885

Abstract

The efficacy of UK-109496, a new azole antifungal agent, was evaluated in an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Oral therapy with UK-109496 at a dosage of 10 or 15 mg/kg of body weight every 8 h was begun 24 h after a lethal or sublethal challenge, and results were compared with those for amphotericin B therapy and untreated controls. UK-109496 eliminated mortality and also reduced the tissue burden of Aspergillus fumigatus 10- to 100-fold in liver and kidney tissues and to a lesser degree in lung tissue, and at the higher dose, no viable organisms were recovered from brain tissue from these animals. Both dosages of UK-109496 decreased or eliminated circulating antigen. The half-life of UK-109496 in rabbits was 2.5 to 3 h, and no accumulation of drug was seen even after 15 doses in either uninfected or infected animals. Thus, UK-109496 shows activity in this rabbit model of invasive aspergillosis. Additional studies are needed to determine the potential of the drug for use in the treatment of this infection.

Full Text

The Full Text of this article is available as a PDF (196.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andriole V. T., Miniter P., George D., Kordick D., Patterson T. F. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S134–S138. doi: 10.1093/clinids/14.supplement_1.s134. [DOI] [PubMed] [Google Scholar]
  2. Bodey G. P., Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):413–437. doi: 10.1007/BF01964057. [DOI] [PubMed] [Google Scholar]
  3. DeGregorio M. W., Lee W. M., Linker C. A., Jacobs R. A., Ries C. A. Fungal infections in patients with acute leukemia. Am J Med. 1982 Oct;73(4):543–548. doi: 10.1016/0002-9343(82)90334-5. [DOI] [PubMed] [Google Scholar]
  4. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  5. George D., Kordick D., Miniter P., Patterson T. F., Andriole V. T. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993 Sep;168(3):692–698. doi: 10.1093/infdis/168.3.692. [DOI] [PubMed] [Google Scholar]
  6. Graybill J. R., Kaster S. R. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis. 1984 Feb;129(2):292–295. [PubMed] [Google Scholar]
  7. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  8. Hostetler J. S., Hanson L. H., Stevens D. A. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992 Feb;36(2):477–480. doi: 10.1128/aac.36.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meyer R. D., Young L. S., Armstrong D., Yu B. Aspergillosis complicating neoplastic disease. Am J Med. 1973 Jan;54(1):6–15. doi: 10.1016/0002-9343(73)90077-6. [DOI] [PubMed] [Google Scholar]
  10. Patterson T. F., George D., Ingersoll R., Miniter P., Andriole V. T. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother. 1991 Oct;35(10):1985–1988. doi: 10.1128/aac.35.10.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Patterson T. F., George D., Miniter P., Andriole V. T. Saperconazole therapy in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother. 1992 Dec;36(12):2681–2685. doi: 10.1128/aac.36.12.2681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Patterson T. F., George D., Miniter P., Andriole V. T. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis. 1991 Sep;164(3):575–580. doi: 10.1093/infdis/164.3.575. [DOI] [PubMed] [Google Scholar]
  13. Patterson T. F., Miniter P., Andriole V. T. Efficacy of fluconazole in experimental invasive aspergillosis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S281–S285. doi: 10.1093/clinids/12.supplement_3.s281. [DOI] [PubMed] [Google Scholar]
  14. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  15. Patterson T. F., Miniter P., Ryan J. L., Andriole V. T. Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis. 1988 Aug;158(2):415–422. doi: 10.1093/infdis/158.2.415. [DOI] [PubMed] [Google Scholar]
  16. Sabetta J. R., Miniter P., Andriole V. T. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infect Dis. 1985 Nov;152(5):946–953. doi: 10.1093/infdis/152.5.946. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES